The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hyperkinesis


Psychiatry related information on Hyperkinesis


High impact information on Hyperkinesis


Chemical compound and disease context of Hyperkinesis

  • OBJECTIVE: Tetrabenazine, a monoamine depleter and dopamine receptor blocker, is used to treat several hyperkinetic movement disorders [16].
  • RESULTS: At day 5, patients with serum valproate levels > or = 45 micrograms/ml were two to seven times as likely as patients with levels < 45 micrograms/ml to show 20% or greater improvement in scores on the manic syndrome subscale, the behavior and ideation subscale, elevated mood, increased activity, motor hyperactivity, and psychosis [17].
  • No consistent beneficial effects on the hyperkinetic movements, abnormal motor function, or ability to carry out normal activities were evident with gamma-vinyl GABA treatment [18].
  • The hyperkinesis is ameliorated by low doses of the psychostimulant D-amphetamine and can be rescued genetically by a transgene encoding SNAP-25, located within the Cm deletion [19].
  • Decreased glucose utilization of the striatum can underlie hyperkinetic movement disorders of various etiologies [20].

Biological context of Hyperkinesis


Anatomical context of Hyperkinesis

  • CONCLUSIONS: Heterogeneity of left ventricular wall thickening can be induced or magnified by dobutamine infusion even in subjects without coronary artery disease, with the inferior wall showing a lack of hyperkinesis, up to relative hypokinesis, in comparison with other myocardial regions [23].
  • The hypothesis is presented that phenytoin induces hyperkinesia by increasing dopaminergic and serotonergic activity in the basal ganglia, and that patients with preexisting basal ganglia damage are the most susceptible [24].
  • These results suggest that implantation of a GABA-releasing source may be an effective alternative to intrathalamic fetal-tissue grafts or lesions as an experimental approach to the treatment of hyperkinetic movement disorders [25].
  • This latter locomotor stimulant effect was suppressed by the dopamine antagonist, haloperidol (50 micrograms/kg, i.p.). Thus, the hypokinetic effect of 30 ng [D-Trp11]neurotensin is independent of dopamine transmission, whereas the hyperkinesia elicited by 750 ng proceeds via an increase in dopamine transmission in the nucleus accumbens [26].
  • Although a single solid graft of embryonic DA neurons can prevent progression of some lesioned-induced behavioral abnormalities such as LD-induced rotation and dystonia, it significantly increases hyperkinetic movements of the contralateral forelimb [27].

Gene context of Hyperkinesis


Analytical, diagnostic and therapeutic context of Hyperkinesis


  1. Pharmacology of blepharospasm-oromandibular dystonia syndrome. Casey, D.E. Neurology (1980) [Pubmed]
  2. Cellular distribution of torsin A and torsin B in normal human brain. Konakova, M., Huynh, D.P., Yong, W., Pulst, S.M. Arch. Neurol. (2001) [Pubmed]
  3. Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys. Neale, R., Gerhardt, S., Fallon, S., Liebman, J.M. Psychopharmacology (Berl.) (1982) [Pubmed]
  4. Palilalia as a symptom of levodopa induced hyperkinesia in Parkinson's disease. Ackermann, H., Ziegler, W., Oertel, W.H. J. Neurol. Neurosurg. Psychiatr. (1989) [Pubmed]
  5. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Pearce, R.K., Jackson, M., Britton, D.R., Shiosaki, K., Jenner, P., Marsden, C.D. Psychopharmacology (Berl.) (1999) [Pubmed]
  6. Treatment of hyperkinetic movement disorders. Jankovic, J. Lancet. Neurol (2009) [Pubmed]
  7. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Jucaite, A., Fernell, E., Halldin, C., Forssberg, H., Farde, L. Biol. Psychiatry (2005) [Pubmed]
  8. GABAergic involvement in motor effects of an adenosine A(2A) receptor agonist in mice. Khisti, R.T., Chopde, C.T., Abraham, E. Neuropharmacology (2000) [Pubmed]
  9. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. Girotti, F., Carella, F., Scigliano, G., Grassi, M.P., Soliveri, P., Giovannini, P., Parati, E., Caraceni, T. J. Neurol. Neurosurg. Psychiatr. (1984) [Pubmed]
  10. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Gerlach, J., Korsgaard, S., Clemmesen, P., Lauersen, A.M., Magelund, G., Noring, U., Povlsen, U.J., Bech, P., Casey, D.E. Acta psychiatrica Scandinavica. (1993) [Pubmed]
  11. Photosensitization and the nervous system in the planarian Dugesia gonocephala. A histochemical, ultrastructural and behavioral investigation. Palladini, G., Margotta, V., Medolago-Albani, L., Hernandez, M.C., Carolei, A., de Michele, T. Cell Tissue Res. (1981) [Pubmed]
  12. Erythrosin B inhibits dopamine transport in rat caudate synaptosomes. Lafferman, J.A., Silbergeld, E.K. Science (1979) [Pubmed]
  13. Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Wang, Q., Bardgett, M.E., Wong, M., Wozniak, D.F., Lou, J., McNeil, B.D., Chen, C., Nardi, A., Reid, D.C., Yamada, K., Ornitz, D.M. Neuron (2002) [Pubmed]
  14. slo K(+) channel gene regulation mediates rapid drug tolerance. Ghezzi, A., Al-Hasan, Y.M., Larios, L.E., Bohm, R.A., Atkinson, N.S. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  15. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Van Raamsdonk, J.M., Pearson, J., Rogers, D.A., Bissada, N., Vogl, A.W., Hayden, M.R., Leavitt, B.R. Hum. Mol. Genet. (2005) [Pubmed]
  16. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Ondo, W.G., Hanna, P.A., Jankovic, J. The American journal of psychiatry. (1999) [Pubmed]
  17. Relation of serum valproate concentration to response in mania. Bowden, C.L., Janicak, P.G., Orsulak, P., Swann, A.C., Davis, J.M., Calabrese, J.R., Goodnick, P., Small, J.G., Rush, A.J., Kimmel, S.E., Risch, S.C., Morris, D.D. The American journal of psychiatry. (1996) [Pubmed]
  18. Gamma-vinyl GABA treatment of Huntington's disease. Scigliano, G., Giovannini, P., Girotti, F., Grassi, M.P., Caraceni, T., Schechter, P.J. Neurology (1984) [Pubmed]
  19. Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder. Wilson, M.C. Neuroscience and biobehavioral reviews. (2000) [Pubmed]
  20. Regional brain glucose metabolism in neuroacanthocytosis. Dubinsky, R.M., Hallett, M., Levey, R., Di Chiro, G. Neurology (1989) [Pubmed]
  21. Involvement of dopamine D2 receptors in the effect of cocaine on sexual behaviour and stretching-yawning of male rats. Ferrari, F., Giuliani, D. Neuropharmacology (1997) [Pubmed]
  22. ACTH neuromodulation of the developing motor system and neonatal learning in the rat. Acker, G.R., Berran, J., Strand, F.L. Peptides (1985) [Pubmed]
  23. Heterogeneity of left ventricular regional wall thickening following dobutamine infusion in normal human subjects. Borges, A.C., Pingitore, A., Cordovil, A., Sicari, R., Baumann, G., Picano, E. Eur. Heart J. (1995) [Pubmed]
  24. Phenytoin-induced hyperkinesia. Lühdorf, K., Lund, M. Epilepsia (1977) [Pubmed]
  25. Intrathalamic implants of GABA-releasing polymer matrices reduce motor impairments in rats with excitotoxically lesioned striata. Rozas, G., Liste, I., Lopez-Martin, E., Guerra, M.J., Kokaia, M., Labandeira-Garcia, J.L. Exp. Neurol. (1996) [Pubmed]
  26. Locomotor effects of [D-Trp11]neurotensin and dopamine transmission in rats. Nouel, D., Costentin, J. Eur. J. Pharmacol. (1994) [Pubmed]
  27. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Steece-Collier, K., Collier, T.J., Danielson, P.D., Kurlan, R., Yurek, D.M., Sladek, J.R. Mov. Disord. (2003) [Pubmed]
  28. Neuropeptide Y and sigma ligand (JO 1784) suppress stress-induced colonic motor disturbances in rats through sigma and cholecystokinin receptors. Gue, M., Junien, J.L., Del Rio, C., Bueno, L. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  29. Immunocytochemical characterization of torsin proteins in mouse brain. Konakova, M., Pulst, S.M. Brain Res. (2001) [Pubmed]
  30. Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. Hess, E.J., Collins, K.A., Wilson, M.C. J. Neurosci. (1996) [Pubmed]
  31. Comparative involvement of 5-HT1, 5-HT2 and 5-HT3 receptors in stress-induced colonic motor alterations in rats. Gué, M., Alary, C., Rio-Lacheze, C.D., Junien, J.L., Buéno, L. Eur. J. Pharmacol. (1993) [Pubmed]
  32. Neocortical and hippocampal EEG in rats during lateral hypothalamic lesion-induced hyperkinesia: relations to behavior and effects of atropine. Whishaw, I.Q., Kolb, B. Physiol. Behav. (1979) [Pubmed]
  33. Effects of methylphenidate on whirler mice: an animal model for hyperkinesis. Sackler, A.M., Weltman, A.S. Life Sci. (1985) [Pubmed]
  34. Opioid activity of lefetamine. De Montis, M.G., Devoto, P., Bucarelli, A., Tagliamonte, A. Pharmacological research communications. (1985) [Pubmed]
  35. Effects of cocaine treatment on the nervous system of planaria (Dugesia gonocephala s. l.). Histochemical and ultrastructural observations. Margotta, V., Caronti, B., Meco, G., Merante, A., Ruggieri, S., Venturini, G., Palladini, G. European journal of histochemistry : EJH. (1997) [Pubmed]
  36. Neostriatal glutamatergic system is involved in the pathogenesis of picrotoxin-induced choreomyoclonic hyperkinesis. Yakimovskii, A.F., Varshavskaya, V.M. Bull. Exp. Biol. Med. (2004) [Pubmed]
WikiGenes - Universities